Related Experiment Video
Updated: May 15, 2026
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Arginine deprivation therapy for malignant melanoma
Jung-Ki Yoon1, Arthur E Frankel, Lynn G Feun
1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA ; Hwasung Public Health Center, Hwasung, South Korea.
Abstract:
Despite recent development of promising immunotherapeutic and targeted drugs, prognosis in patients with advanced melanoma remains poor, and a cure for this disease remains elusive in most patients. The success of melanoma therapy depends on a better understanding of the biology of melanoma and development of drugs that effectively target the relevant genes or proteins essential for tumor cell survival. Melanoma cells frequently lack argininosuccinate synthetase, an essential enzyme for arginine synthesis, and as a result they become dependent on the availability of exogenous arginine. Accordingly, a therapeutic approach involving depletion of available arginine has been shown to be effective in preclinical studies. Early clinical studies have demonstrated sufficient antitumor activity to give rise to cautious optimism. In this article, the rationale for arginine deprivation therapy is discussed. Additionally, various strategies for depleting arginine are discussed and the preclinical and clinical investigations of arginine deprivation therapy in melanoma are reviewed.
Insights
Arginine deprivation therapy shows promise for advanced melanoma by targeting cancer cells
Area of Science:
- Oncology
- Biochemistry
- Cancer Biology
Background:
- Advanced melanoma prognosis remains poor despite new treatments.
- Melanoma cells often lack argininosuccinate synthetase, creating arginine dependency.
- Targeting essential tumor cell survival pathways is crucial for effective melanoma therapy.
Purpose of the Study:
- To discuss the rationale behind arginine deprivation therapy for melanoma.
- To review preclinical and clinical investigations of arginine deprivation strategies.
- To explore various methods for depleting arginine in melanoma treatment.
Main Methods:
- Review of preclinical studies on arginine deprivation.
- Analysis of early clinical trial data for arginine deprivation therapy.
- Discussion of biochemical pathways related to arginine synthesis in melanoma.
Main Results:
- Arginine deprivation therapy has demonstrated antitumor activity in preclinical models.
- Early clinical studies indicate cautious optimism for arginine deprivation's efficacy.
- Melanoma cell dependency on exogenous arginine presents a viable therapeutic target.
Conclusions:
- Arginine deprivation therapy is a promising strategy for advanced melanoma.
- Further research and clinical trials are warranted to optimize arginine deprivation approaches.
- Understanding melanoma's metabolic vulnerabilities is key to developing novel treatments.
